NRX Pharmaceuticals Ratios (2024-2025) | NRXP

Ratios Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025
Profitability
Gross Margin (Quarter) 59.92%58.49%
EBT Margin (Quarter) 2,696.09%-1,661.98%-538.25%
EBIT Margin (Quarter) 2,607.83%-1,662.81%-470.40%
EBITDA Margin (Quarter) 2,607.83%-2,433.88%-876.30%
Operating Margin (Quarter) 2,607.83%-1,662.81%-470.40%
Net Margin (Quarter) 2,696.09%-1,661.98%-538.25%
FCF Margin (Quarter) 1,596.09%-1,195.04%-377.62%
Efficiency
Assets Average (Quarter) 4.53M4.86M4.06M5.62M6.21M9.92M13.98M
Equity Average (Quarter) -16.73M-18.61M-21.02M-24.19M-30.39M-30.68M-20.85M
Invested Capital (Quarter) -15.04M-17.45M-16.92M-22.90M-15.31M-19.35M-25.60M-15.94M
Asset Utilization Ratio (Quarter) -0.060.020.09
Leverage & Solvency
Interest Coverage Ratio (Quarter) -26.08-6.89
Debt to Equity (Quarter) 0.00-0.05-0.10-0.01-0.39-0.46-0.01
Debt Ratio (Quarter) 0.010.180.430.091.303.360.01
Equity Ratio (Quarter) -3.98-3.49-4.22-6.36-3.32-7.36-1.72-1.23
Times Interest Earned (Quarter) -26.08-6.89
Valuation
Enterprise Value (Quarter) -1.32M-1.90M-1.60M-1.44M-5.55M-2.90M-7.20M-7.80M
Return Ratios
Return on Sales (Quarter) 26.96%81.25%-16.62%-5.38%
Return on Capital Employed (Quarter) 1.04%0.60%0.38%0.46%1.11%
Return on Assets (Quarter) -4.61%-2.91%-2.09%-1.41%-1.21%
Return on Equity (Quarter) 0.89%0.68%0.43%0.46%0.81%